TABLE 3.
In vitro activities of rezafungin and comparators against 122 clinical C. auris isolates as determined by EUCAST E.Def 7.3.1a
| Drug | Value for MIC (mg/liter): |
MIC range (mg/liter) | Modal MIC (mg/liter) | MIC50 (mg/liter) | WT-UL (mg/liter) |
||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ≤0.004 | 0.008 | 0.016 | 0.03 | 0.06 | 0.125 | 0.25 | 0.5 | 1 | 2 | 4 | 8 | 16 | 32 | ≥64 | Visual | 97.5% | 99% | ||||
| Rezafungin | 3 | 22 | 63 | 16 | 7 | 3 | 6 | 2 | 0.06 to 16 | 0.25 | 0.25 | 0.5 | 0.5 | 0.5 | |||||||
| Anidulafunginb | 1 | 11 | 35 | 30 | 12 | 12 | 11 | 2 | 1 | 7 | 0.016 to >32 | 0.06 | 0.125 | 0.25 | 0.25 | 0.5 | |||||
| Micafunginb | 5 | 30 | 70 | 9 | 8 | 0.03 to >32 | 0.125 | 0.125 | 0.25 | 0.25 | 0.25 | ||||||||||
| Amphotericin Bb | 14 | 108 | 0.5 to 1 | 1 | 1 | 2 | NP | NP | |||||||||||||
| Fluconazoleb | 1 | 2 | 10 | 109 | 0.5 to ≥64 | ≥64 | ≥64 | NP | NP | NP | |||||||||||
| Voriconazoleb | 1 | 1 | 1 | 16 | 13 | 34 | 38 | 13 | 5 | ≤0.004 to 4 | Bimodal | 0.5 | 4 | 4 | 8 | ||||||
| Isavuconazoleb | 20 | 1 | 1 | 19 | 9 | 19 | 21 | 21 | 6 | 5 | ≤0.004 to 2 | Trimodal | 0.125 | 0.016 or 2 | NP | NP | |||||
a
The shaded areas indicate that concentrations were not tested for the compound. MIC50s are in boldface. The underlined values are the modal MICs for unimodal distributions but the lowest MIC peak for multimodal distributions, thus illustrating the modal MIC of the presumed wild-type distribution.
b
The MIC distributions for comparator antifungals against C. auris were compiled from reference 20.